Excited to present the first major work after starting our lab at Stanford and the Arc this year: CRISPR-All, a unified genetic perturbation language for programming any major type of genetic perturbation simultaneously, in any combination, at genome scale, in human cells.

We're excited to release tcellMIL, an attention-based multiple instance learning model for predicting patient outcomes after CAR T cell therapy for lymphoma and nominating cell design strategies in #neurips2025 AI4D3!

It's exciting to share our mini-review on #Treg cell therapies out today in Frontiers in Immunology! Earning a #NobelPrize this year, Tregs have been tested in >69 clinical trials and are moving towards initial approvals.

This would not be possible without my mentors, especially Crystal Mackall, @sylviaplevritis, @GarryPNolan, Sean Bendall, David Miklos, and Michael Gold - THANK YOU!

Today is my first day as an Assistant Professor of Medicine at Stanford University! My research program is focused on understanding and enhancing engineered T cell immunotherapies for cancer and immune-mediated diseases. If interested in joining please reach out!

Very proud of Anne Marijn Kramer to present 2 orals and a poster at #ASH2024, especially our work on CD22-CAR! Session 702 Dec 9 at 2:45 PM San Diego Convention Center, Room 6CF Title: CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with IEC-HS

So proud of Kelvin Mo to give his first talk at #ASH2024! Session 702 Dec 7 at 4:00 PM Manchester Grand Hyatt San Diego, Grand Hall C Title: CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL

What an honor to give my first invited talk at #ASH2024. I am so grateful to my mentors Crystal Mackall, Sylvia Plevritis, and David Miklos for enabling me to get here! Dec 8 at 4:30 PM, San Diego Conv. Center, Room 33 Cellular Heterogeneity and Relationship to Clinical Outcomes

Our Stanford Center for Cancer Cell Therapy is excited to offer a Postdoctoral Fellow position at the interface between machine learning and T cell therapies:

Boom Capital is hiring a Chief of Staff. 🚀 This is one of our most important hires. You'll liaise with our in-house scientific society and impact every aspect of a VC firm, serving unprecedented ideas, scientists and engineers. Join https://t.co/30lUgMZk1b and apply here:

Grateful to give an invited talk at the 6th Annual #Treg-Directed Therapies Summit! Please join us in Boston this May 21-23. https://t.co/7gzWIYGwVP

Humbled and grateful to be selected as a 2023 Bridge Fellow by the @parkerici to push forward CAR T immunotherapy research.

Grateful to @CGT_Live to publish this summary of our work with @MackallLab, David Miklos, @BitaSahaf and team that I presented at @AACR!

Honored to be interviewed by @10xGenomics to discuss our work with @SRamakrishna_MD , @MackallLab, and @michelle_monje on GD2-CAR T cell therapy for pediatric brain cancer.

Thanks @TeikoBio for highlighting our work with @jayspiegel25, @BitaSahaf, @MackallLab, David Miklos, and team on defining the role of CAR Treg cells in progression following #CART therapy for lymphoma.

Thanks to @statnews for covering our work identifying CAR Treg cells as limiting efficacy, toxicity, and expansion of CD19-CAR in lymphoma. Full article in @NatureMedicine here: https://t.co/eXErZXEAQs.

To accelerate development of effective T cell therapies for cancer, there's an urgent need to decipher the attributes of the ideal therapeutic T cell Read the Meeting Report from the Parker Institute & 10x Genomics @SamanthaBucktr1 @parkerici @10xGenomics https://t.co/UKG6JlZafY

In collaboration with @parkerici scientists and @10xGenomics, we wrote a commentary on "Advancing T cell–based cancer therapy with single-cell technologies" just out in @NatureMedicine:

We're grateful to @BitaSahaf and the whole #CCSU for enabling correlative studies like this.

Single-cell proteomic profiling of circulating #CART cells in patients treated with CD19-CAR shows that CD4+Helios+ CAR #Treg cells on day 7 after infusion are associated with progressive disease & less severe neurotoxicity in patients with #LBCL. https://t.co/xteFBA31SP